<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?properties manuscript?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">9607835</journal-id><journal-id journal-id-type="pubmed-jr-id">20545</journal-id><journal-id journal-id-type="nlm-ta">Mol Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Mol. Psychiatry</journal-id><journal-title-group><journal-title>Molecular psychiatry</journal-title></journal-title-group><issn pub-type="ppub">1359-4184</issn><issn pub-type="epub">1476-5578</issn></journal-meta><article-meta><article-id pub-id-type="pmid">28373691</article-id><article-id pub-id-type="pmc">5507298</article-id><article-id pub-id-type="doi">10.1038/mp.2017.65</article-id><article-id pub-id-type="manuscript">EMS71665</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Blocking human fear memory with the matrix metalloproteinase inhibitor doxycycline</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bach</surname><given-names>Dominik R</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib><contrib contrib-type="author"><name><surname>Tzovara</surname><given-names>Athina</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Vunder</surname><given-names>Johanna</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib></contrib-group><aff id="A1">
<label>1</label>Division of Clinical Psychiatry Research, University of Zurich, 8032 Zurich, Switzerland</aff><aff id="A2">
<label>2</label>Neuroscience Centre Zurich, University of Zurich, 8057 Zurich, Switzerland</aff><aff id="A3">
<label>3</label>Wellcome Trust Centre for Neuroimaging and Max Planck UCL Centre for Computational Psychiatry and Ageing Research, University College London, London WC1N 3BG, UK</aff><author-notes><corresp id="CR1"><label>*</label>Corresponding author: <email>dominik.bach@uzh.ch</email></corresp><fn id="FN1" fn-type="con"><p id="P1"><bold>Author contributions</bold></p><p id="P2">DRB conceived the study. DRB and AT designed the study. JV and DRB collected the data. DRB analysed the results. DRB, AT and JV wrote the manuscript.</p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>3</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>04</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><elocation-id>10.1038/mp.2017.65</elocation-id><permissions><license><license-p>Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:<ext-link ext-link-type="uri" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</ext-link></license-p></license></permissions><abstract><p id="P3">Learning to predict threat is a fundamental ability of many biological organisms, and a
laboratory model for anxiety disorders. Interfering with such memories in humans
would be of high clinical relevance. Based on studies in cell cultures and slice
preparations, it is hypothesised that synaptic remodelling required for threat
learning involves the extracellular enzyme matrix metalloproteinase 9 (MMP-9).
However, in vivo evidence for this proposal is lacking. Here we investigate
human Pavlovian fear conditioning under the blood-brain barrier crossing MMP
inhibitor doxycyline in a pre-registered, randomised, double-blind,
placebo-controlled trial. We find that recall of threat memory, measured with
fear-potentiated startle 7 days after acquisition, is attenuated by about 60% in
individuals who were under doxycycline during acquisition. This threat memory
impairment is also reflected in increased behavioural surprise signals to the
CS+ during subsequent re-learning, and already late during initial acquisition.
Our findings support an emerging view that extracellular signalling pathways are
crucially required for threat memory formation. Furthermore, they suggest novel
pharmacological methods for primary prevention and treatment of posttraumatic
stress disorder.</p></abstract></article-meta></front><body><sec sec-type="intro" id="S1"><title>Introduction</title><p id="P4">Learning to predict threat is a fundamental ability of many biological organisms, yet in anxiety disorders dysfunctional overprediction of threat causes tremendous suffering. A dedicated threat memory system in many mammals including humans can be probed using Pavlovian discriminative fear conditioning.<xref rid="R1" ref-type="bibr">1</xref> In this paradigm, an initially neutral cue (conditioned stimulus, CS+) is contingently paired with an aversive event (unconditioned stimulus, US), while a different cue (CS-) is not. Crucial pivot in learning US predictions is a synaptic re-configuration that leads to long-term potentiation (LTP) of amygdala neurons with converging CS and US input.<xref rid="R1" ref-type="bibr">1</xref> Interfering with threat memory in Pavlovian fear conditioning is being investigated as preclinical model for treatment of posttraumatic stress disorder.<xref rid="R2" ref-type="bibr">2</xref> However, pharmacological manipulation of threat memories in humans has been difficult. The most direct mechanism of action used in non-human research - broad spectrum protein synthesis inhibition<xref rid="R3" ref-type="bibr">3</xref> - is not applicable in humans.<xref rid="R4" ref-type="bibr">4</xref> A more specific option is propranolol, which interferes with human threat learning possibly by inhibiting synthesis of proteins required for synaptic plasticity.<xref rid="R2" ref-type="bibr">2</xref>, <xref rid="R5" ref-type="bibr">5</xref> However, propranolol may be less effective in individuals with high trait anxiety.<xref rid="R6" ref-type="bibr">6</xref> In this paper, we sought to inhibit synaptic remodelling by targeting an extracellular signalling pathway.</p><p id="P5">In the past decades, evidence has accumulated for a role of extracellular matrix in
memory formation.<xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R8" ref-type="bibr">8</xref> In terms of its structure, extracellular matrix is organised
in perineuronal nets (PNN).<xref rid="R9" ref-type="bibr">9</xref> Their integrity
is crucial for memory storage, including threat memory.<xref rid="R10" ref-type="bibr">10</xref>&#x02013;<xref rid="R12" ref-type="bibr">12</xref>
Functionally, the signalling pathway that induces LTP appears to involve
extracellular enzymes, and specifically matrix metalloproteinase 9 (MMP-9).<xref rid="R7" ref-type="bibr">7</xref> In slices, MMP-9 inhibition or knock-out
reduces long-term potentiation.<xref rid="R13" ref-type="bibr">13</xref>&#x02013;<xref rid="R16" ref-type="bibr">16</xref> Interestingly,
active MMP-9 alone is sufficient to induce LTP.<xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R14" ref-type="bibr">14</xref> In vivo, MMP-9 inhibition
appears to impact on spatial/contextual memory in non-human mammals.<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R18" ref-type="bibr">18</xref>
While the precise mechanism by which MMP-9 takes part in synaptic circuit
remodelling remains elusive,<xref rid="R7" ref-type="bibr">7</xref> these findings
suggest that MMP-9 may be required for formation of human fear memories. Here, we
sought to impair human Pavlovian fear conditioning with the tetracycline antibiotic
doxycycline, a blood-brain barrier crossing<xref rid="R19" ref-type="bibr">19</xref>
in vivo and in vitro MMP-9 inhibitor.<xref rid="R20" ref-type="bibr">20</xref>,
<xref rid="R21" ref-type="bibr">21</xref> To isolate effects of the drug on fear
acquisition/consolidation from direct effects on retrieval, we trained participants
under doxycycline or placebo, and tested fear retention 7 days later.</p><p id="P6">Unlike in rodent species, fear conditioning in humans does not elicit overt behavioural responses to the CS. It is usually quantified using readouts from the automomic nervous system such as skin conductance responses (SCR),<xref rid="R22" ref-type="bibr">22</xref>&#x02013;<xref rid="R24" ref-type="bibr">24</xref> or by its interaction with an innate startle response, termed fear-potentiated startle.<xref rid="R25" ref-type="bibr">25</xref>&#x02013;<xref rid="R27" ref-type="bibr">27</xref> The latter method is the most sensitive way to measure fear retention after initial learning,<xref rid="R28" ref-type="bibr">28</xref> but during initial learning the presentation of startle stimuli inhibits fear acquisition.<xref rid="R29" ref-type="bibr">29</xref> Hence our primary outcome measure was fear-potentiated startle eye blink response (SEBR) during fear retention. To quantify the progress of fear learning and re-learning where no startle stimuli were delivered, we relied on SCR. While fear-potentiated startle scales with CS/US association strength,<xref rid="R30" ref-type="bibr">30</xref> SCR are suggested to reflect CS-specific associability,<xref rid="R31" ref-type="bibr">31</xref>, <xref rid="R32" ref-type="bibr">32</xref> which is based on a weighted average of surprise about the previous outcomes following this CS.<xref rid="R33" ref-type="bibr">33</xref>
</p></sec><sec sec-type="materials | methods" id="S2"><title>Materials and Methods</title><sec sec-type="subjects" id="S3"><title>Participants</title><p id="P7">Participants were recruited from the general population (n = 80; 40 per group; 20 female per group). Two participants did not complete acquisition visit 2: one due to vomiting immediately after ingesting the drug, and another due to an irresolvable computer failure. Two further participants were excluded from analysis: one due to failure of the startle sound equipment on visit 3, and the other did not comply with instructions and pressed response keys on less than 2% of trials on both visits. Re-including these participants into the analysis did not change any of the statistical inference results. The reported final sample therefore comprised 76 individuals, 38 per group (<xref ref-type="fig" rid="F1">Figure 1a</xref>). The groups did not differ in age, gender, body-mass index, or baseline personality measures (<xref ref-type="table" rid="T1">Table 1</xref>). All participants were screened for health conditions by a physician (see <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref> for in- and exclusion criteria). The study was conducted in accord with the Declaration of Helsinki and approved by the governmental research ethics committee (Kantonale Ethikkomission Zurich, KEK-ZH 2014-0669) and the Swiss Agency for Therapeutic Products (Swissmedic, 2015DR1136). All participants gave written informed consent using a form approved by the ethics committee. The study was pre-registered at the primary ISRCTN registry (ISRCTN66987216) and at the Swiss Federal Complementary Database (KOFAM; SNCTP000001439).</p></sec><sec id="S4"><title>Power analysis</title><p id="P8">To determine required sample size, we conducted a power analysis (using G*power<xref rid="R34" ref-type="bibr">34</xref>) based on a pilot study with the same setup,<xref rid="R28" ref-type="bibr">28</xref> in which the effect size for a CS+/CS- SEBR difference in an untreated control group was (Cohen's) d = 1.17. Under the assumption of equal variance in a doxycycline-treated group, a fear memory reduction of 50% would correspond to an effect size of d = 0.59. Thus, a sample size of N = 74 was required to achieve 80% power at an alpha rate of 0.05. We recruited N = 80 participants to allow for attrition.</p></sec><sec id="S5"><title>Study medication</title><p id="P9">The study medication was doxycycline, brand name Vibramycin<sup>&#x000ae;</sup> (Pfizer). The study dose of 200 mg was based on the smallest antibiotic dose recommended by the manufacturer, in order to reduce side effects. Peak CSF concentrations are reached at approximately 180 min after oral administration.<xref rid="R19" ref-type="bibr">19</xref> The drug's half-life is approximately 16 hours according to manufacturer's information; such the drug was cleared by more than 99.9% at the retention test 7 days after ingestion. A GMP-licensed pharmacy (Kantonsapotheke Z&#x000fc;rich) manufactured, blinded and randomized the study medication separately for males and females; mannitol was used as placebo. Randomisation code was broken after the last participant completed the study (LPLV), and after all data were checked for consistency.</p></sec><sec sec-type="methods" id="S6"><title>Procedure</title><sec id="S7"><title>Screening visit 1 (day -7 to day -1)</title><p id="P10">Study procedure is summarised in <xref ref-type="fig" rid="F1">figure 1b</xref>. On visit 1, we determined US intensity and habituated participants to startle sounds, performed medical examination to check exclusion criteria (<xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>), and measured weight/height to compute body-mass index (BMI).</p></sec><sec id="S8"><title>Acquisition visit 2 (day 0)</title><p id="P11">Acquisition visit 2 took part in the morning hours between 08.00 and 13.00. Participants
filled in the German translations of the State-Trait Anxiety Inventory<xref rid="R35" ref-type="bibr">35</xref> and Beck's Depression
Inventory (BDI)<xref rid="R36" ref-type="bibr">36</xref> before ingesting
the study medication. During a 180-minute metabolisation interval, they were
kept under surveillance of study staff. Next, participants performed a
15-minute N-back working memory task and a paper-and-pencil version of the
d2 attention test. Then the fear acquisition protocol started. This was a
standard discriminant delay conditioning paradigm with 160 trials (80 CS+,
80 CS-) in 2 blocks (<xref ref-type="fig" rid="F1">Figure 1c</xref>). The
CS+ co-terminated with an electric stimulation as aversive US (<xref ref-type="supplementary-material" rid="SD1">Supplementary
Information</xref>) in 50% of trials. CS were a blue or red screen
background presented for 4 s, while the screen was black during the inter
trial interval, randomly determined to be 7 s, 9 s, or 11 s. Trial sequence
was randomly balanced for each participant, with the restriction that the
first trial of each block was always a reinforced CS+. As an incidental
task, participants were instructed to press a key with right index or middle
finger to indicate CS colour. Colour-CS and colour-button associations were
balanced across participants. Colour-CS association had no impact on any
outcome measure.</p></sec><sec id="S9"><title>Retention visit 3 (day 7)</title><p id="P12">Participants were instructed that they might receive US, but that CS/US contingency was determined by the computer and unknown to the study assistant. They saw 40 CS (20 CS+/20 CS-) in randomly balanced order, and heard a startle probe (<xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>) 3.5 s after onset of all CS, but never received a US. Note that the motoric startle response makes SCR data from this session unusable. Immediately afterwards, we measured re-learning over 80 trials by co-terminating 50% of CS with a US over 80 trials, but without startle sounds.</p></sec><sec id="S10"><title>N-back task</title><p id="P13">Random letters were shown on the screen for 500 ms followed by a fixation cross for 2500 ms. Participants were tasked to indicate on each trial whether the letter matched the one from N steps back. N was constant (1/2/3) within each of three blocks.<xref rid="R37" ref-type="bibr">37</xref> Each block contained 70 non-targets and 30 targets.</p></sec><sec id="S11"><title>d2 test</title><p id="P14">The d2-test<xref rid="R38" ref-type="bibr">38</xref> is designed to measure sustained attention over 5 minutes. Participants are given 20 seconds to work on each of 14 rows; in each row their task is to cross every letter "d" marked with two lines above and/or below, while leaving out the letter "d" not marked with two lines, as well as the letter "p".</p></sec><sec id="S12"><title>Outcome measures</title><p id="P15">Primary outcome measure was startle potentiation during the retention test, measured as
SEBR from orbicularis oculi electromyogram (<xref ref-type="supplementary-material" rid="SD1">Supplementary
Information</xref>). There were no missing data in the primary outcome.
Secondary outcome measure was SCR. No SCR data were available for 3
participants during acquisition (1 placebo, 2 doxycycline) and for 1
participant during re-learning (placebo), due to electrode detachment. Due
to artefacts, a small number of individual trials in some participants were
excluded (&#x0003c; 1.5% of trials, see <xref ref-type="supplementary-material" rid="SD1">Supplementary
Information</xref> for details).</p></sec></sec><sec id="S13"><title>Psychophysiological modelling</title><p id="P16">For psychophysiological analysis, we used a Matlab toolbox for psychophysiological
modelling, PsPM 3.0 (pspm.sourceforge.net). SEBR processing was performed using
the most sensitive method from a previous methodological comparison using the
same setup<xref rid="R28" ref-type="bibr">28</xref> (<xref ref-type="supplementary-material" rid="SD1">Supplementary
Information</xref>). This procedure builds on a psychophysiological model
(PsPM)<xref rid="R39" ref-type="bibr">39</xref> and quantifies, for each
trial, amplitude of the SEBR by linear regression onto a canonical SEBR with
variable onset.<xref rid="R28" ref-type="bibr">28</xref> Skin conductance was
analysed by non-linear inversion of a PsPM that describes the anticipatory
SCR<xref rid="R23" ref-type="bibr">23</xref>, <xref rid="R24" ref-type="bibr">24</xref> under a canonical response function.<xref rid="R40" ref-type="bibr">40</xref>, <xref rid="R41" ref-type="bibr">41</xref>
</p></sec><sec id="S14"><title>Statistical analysis</title><p id="P17">Statistical analysis was done in R (<ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/">www.r-project.org</ext-link>), version 3.3.1, using aov() for ANOVAs. R package nlme, version 3.1.128, was used for linear mixed effects (LME) models (<xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>).<xref rid="R42" ref-type="bibr">42</xref> We analysed trial-wise SEBR in a 2 (drug) x 2 (CS+/CS-) x 20 (trial) multistratum repeated-measures ANOVA. Because trial sequence was not the same for each participant, habituation may affect CS+ and CS- differently in the two groups. Therefore, results were confirmed in a LME model that accounts for the linear effect of time (trial number across CS). For SCR, only trials without US entered analysis. As there are uneven numbers of CS+US- and CS- trials, we averaged within mini-blocks of 10 trials, and entered these averages into a 2 (drug) x 2 (CS+/CS-) x 16 (mini-block) repeated-measures ANOVA (acquisition) or 2 (drug) x 2 (CS+/CS-) x 8 ANOVA (re-learning). Participants for whom all trials in at least one mini-block were missing were excluded (<xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>). Results were confirmed in a trial-wise LME, in which missing data points were removed on a trial-by-trial basis, as this model can deal with unbalanced data.</p><sec id="S15"><title>N-back task</title><p id="P18">Performance was averaged within conditions and analysed in a 3 (N-back) x 2 (target/non-target) repeated-measures ANOVA.</p></sec><sec id="S16"><title>Control measures</title><p id="P19">Control measures were tested for group differences with independent samples t-tests, without correction for multiple comparison. We tested the following measures: age, weight, BMI, BDI sum score, STAI sum scores, electric current used as US, difference in averaged ratings of the same 14 pain stimuli before and after the acquisition test. Further, we tested the following 3 outcomes of the d2-test: performance of attention (marked - missed targets), speed (total number of targets processed), error percentage (all errors divided by total processed targets). During fear acquisition, we analysed performance (any key pressed), accuracy (correct key pressed), and reaction times. No t-test for group differences on any control measure yielded a statistically significant result. Entering anxiety and depression scores, or pain habituation during the acquisition session, into the statistical model as a covariate, together with the covariate x CS interaction, had no impact on statistical significance of the primary outcome (interaction drug x CS during retention).</p></sec></sec></sec><sec sec-type="results" id="S17"><title>Results</title><p id="P20">3.5 hours after orally ingesting placebo or 200 mg doxycyline, participants performed a discriminant delay fear conditioning task (<xref ref-type="fig" rid="F1">figure 1c</xref>) in which the CS+ co-terminated with an aversive electrical stimulation in 50% of trials, while the CS- was never reinforced. To reduce a potential impact of variability in learning speed, we overtrained participants in 160 trials (80 CS+, 80 CS-). Before the fear acquisition task started, we ensured that doxycycline had no impact on pain perception, attention in the d2 test, or memory on a seconds-timescale in a 1/2/3-back task (see <xref ref-type="sec" rid="S2">methods</xref>, <xref ref-type="table" rid="T1">Table 1</xref>, <xref ref-type="fig" rid="F2">Figure 2</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>). Performance in an incidental task during fear acquisition was also unchanged by the drug.</p><p id="P21">Primary outcome was fear retention under extinction, 7 days after acquisition (see <xref ref-type="fig" rid="F3">figure 3a</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>).
Fear-potentiated startle was measured as startle eye blink response (SEBR) to
acoustic startle probes on each of 40 extinction trials, and analysed in a
repeated-measures ANOVA. Threat memory (i.e. CS+/CS- difference in SEBR) was
attenuated by about 60% in the doxycycline as compared to placebo group (interaction
drug x CS: p = .01). This initial analysis did not take into account that the
sequence of CS+ and CS- was randomised for each participant, and might have been
slightly different between the two groups. This is why we replicated these results
in a linear mixed effects (LME) model with trial number as predictor across CS types
(see <xref ref-type="supplementary-material" rid="SD1">Supplementary
Information</xref> for details). This analysis revealed the same group
difference in threat memory (interaction drug x CS: p = .021). Finally, there was no
difference between the groups in terms of extinction (i.e. no drug x trial x CS
interaction).</p><p id="P22">Next, we analysed the re-learning session, which immediately followed the retention session and always started with a reinforced CS+ trial. No startle probes were used during this session in order to allow unimpaired learning.<xref rid="R29" ref-type="bibr">29</xref> Instead we analysed SCR, which are thought to reflect a Pearce-Hall type associability signal,<xref rid="R33" ref-type="bibr">33</xref> i.e. a running average of surprise about the outcome on previous trials.<xref rid="R31" ref-type="bibr">31</xref>, <xref rid="R32" ref-type="bibr">32</xref> If fear memory were weak during the non-reinforced retention test, one would expect greater surprise about the presence of a US during the reinforced re-learning session. This would imply a larger CS+/CS- difference in SCR, particular in the beginning of the re-learning session. Indeed during re-learning, SCR surprise signals were larger in the doxycycline than in the placebo group in a block-wise ANOVA that was ignorant about trial sequence, and in a linear mixed effects model that took account of trial sequence (interaction drug x CS; ANOVA: p = 0.010; LME: p &#x0003c; .001; <xref ref-type="fig" rid="F3">figure 3b</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>). The more sensitive LME furthermore indicated that enlarged surprise signals upon CS+ presentation in the doxycyline group decreased over time (interaction drug x CS x time; p = .028), as expected (see <xref ref-type="fig" rid="F3">figure 3b</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>). These findings are consistent with weaker threat memory at the start of the re-learning session.</p><p id="P23">Finally, we sought to elucidate whether doxycycline acts on memory consolidation after acquisition alone, or whether an effect of the drug was already observable during acquisition. This was an exploratory analysis. As in the re-learning session, we found a larger CS+/CS- difference in SCR in the doxycycline than placebo group, potentially indicating greater surprise about the presence of the US in this group (interaction drug x CS; ANOVA: p &#x0003c; 0.001; LME: p &#x0003c; .001; see <xref ref-type="fig" rid="F3">figure 3c</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>). This pattern could be explained if the neural system, for each of the CS, keeps track of recent surprise about CS outcome, but fails to appropriately update outcome predictions. Such model is in keeping with our initial result that performance in a 1/2/3-back task, addressing memory on a time scale of seconds, was intact in the doxycycline group. According to this interpretation, the group difference in surprise signals should be small in the beginning of the session (when both groups have not yet formed CS/US associations) and increase towards the end (when the placebo group has formed stronger associations). This was indeed the case: The LME indicated that enlarged surprise signals upon CS+ presentation in the doxycyline group were not found in earlier but in later trials of the learning session (interaction Drug x CS x Time; p = .021), and this appeared to start after about 40 trials (see <xref ref-type="fig" rid="F3">figure 3c</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Information</xref>).</p></sec><sec sec-type="discussion" id="S18"><title>Discussion</title><p id="P24">In this paper, we addressed inhibition of human fear conditioning with the MMP inhibitor
doxcycyline. In the primary outcome, fear-potentiated startle, we found reduced fear
memory retention in those participants who were trained under doxycycline. This
attenuated fear memory was also evident by increased surprise in response to the CS+
during re-learning directly after the retention test, as compared to a placebo
group. Because doxycycline was ingested before the acquisition session, this raises
a question as to whether doxycycline impacts already on threat memory acquisition,
or only later on consolidation. Analysis of the acquisition session provides some
evidence for the former view, i.e. that doxycycline impacts on threat memory already
during training session. However, it does not impair sensory memory on a time scale
of seconds, as shown by unimpaired performance in an N-back task.</p><p id="P25">Doxcycline is a potent inhibitor of human MMP-9 and other MMPs.<xref rid="R20" ref-type="bibr">20</xref>, <xref rid="R21" ref-type="bibr">21</xref> Our results are in keeping with a model in which human amygdala-dependent threat memory requires extracellular MMP signalling for synaptic remodelling. Because in our human model we cannot conclusively rule out that other molecular targets of doxycycline contribute to memory impairment, converging evidence with other human MMP inhibitors would be desirable. Doxycycline has been reported to interact with mitochondrial function,<xref rid="R43" ref-type="bibr">43</xref> and less consistently, with mammalian protein synthesis.<xref rid="R44" ref-type="bibr">44</xref> However, a possible relation of these molecular targets to synaptic plasticity or to memory formation is not established. They therefore appear as less likely to underlie the results reported here. Whether doxycycline also impacts on human hippocampus-dependent, spatial or semantic memory, as previously hypothesised,<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R18" ref-type="bibr">18</xref> remains to be determined. Early human work performed in the context of sleep research has provided some hints that doxycycline may have an impact on semantic memory<xref rid="R45" ref-type="bibr">45</xref> but also pointed towards a potential interaction with REM sleep.<xref rid="R46" ref-type="bibr">46</xref>
</p><p id="P26">Our primary outcome, fear-potentiated startle, is a well-established measure of fear memory strength in many species,<xref rid="R25" ref-type="bibr">25</xref>, <xref rid="R47" ref-type="bibr">47</xref>&#x02013;<xref rid="R51" ref-type="bibr">51</xref> such that the impact of doxycycline on fear retention in this measure can be unambiguously interpreted. In contrast, our analysis of its effect on fear acquisition relies on SCR. Under native conditions, averaged SCR across an entire experiment are often taken as in index of association strength,<xref rid="R22" ref-type="bibr">22</xref> but their fluctuations over time appear to be more consistent with an associability signal.<xref rid="R31" ref-type="bibr">31</xref>, <xref rid="R32" ref-type="bibr">32</xref> The former view is justified because on average, associability is higher for a partially reinforced CS+ than a CS-, but under a pharmacological manipulation, associability and association strength may be decoupled. In the current experiment, it appears that sensory memory is intact under doxycyline, as indexed by results from the 1/2/3-back task. We suggest that the fear learning system stores a running average of surprise about previous trial outcomes, but that it fails to appropriately update threat predictions. This would lead to a continued occurrence of unpredicted US, which would be reflected in higher associability of CS+ in the doxcycline group. In the placebo group, after establishing the threat prediction, SCR to the CS+ would tend to habituate faster as the US becomes predicted and associability decreases. Indeed, we show that SCR to CS+ are greater in the doxycycline than placebo group after about 40 trials into the experiment. Our interpretation relies on an impact of doxycline on updating threat predictions, but not storage of previous trial outcomes. This is in keeping with an impact of MMP-9 inhibitors on late LTP, but not on other synaptic plasticity mechanisms such as early LTP and paired-pulse facilitation,<xref rid="R7" ref-type="bibr">7</xref> but requires confirmation on a molecular level.</p><p id="P27">While evidence for a role of MMP-9 in LTP is mounting, its mechanism of action is unknown. In slices and cell cultures, MMP-9 appears to be transported to synapses at times of neural activity,<xref rid="R52" ref-type="bibr">52</xref> colocalises with NMDA- and AMPA-receptors,<xref rid="R53" ref-type="bibr">53</xref> and impacts on spine re-modelling.<xref rid="R14" ref-type="bibr">14</xref> However, its proteolytic target remains elusive. It has been hypothesised that MMP-9 activates a signalling pathway that ultimately leads integrins to direct AMPA receptors into the synaptic membrane.<xref rid="R7" ref-type="bibr">7</xref> Others have proposed that MMP-9 is involved in remodelling extracellular matrix structure which according to this model enjoys a fundamental role in memory storage<xref rid="R8" ref-type="bibr">8</xref> and enables long-term stability of threat memories, which - after hour-timescale consolidation - last up to a life time.<xref rid="R54" ref-type="bibr">54</xref></p><p id="P28">Such uncertainty notwithstanding, our findings have potentially direct therapeutic implications. They suggest that tetracycline antibiotics - all of which are MMP inhibitors<xref rid="R20" ref-type="bibr">20</xref> - could be used for primary prevention of fear memory acquisition in persons known in advance to be potentially exposed to trauma. Furthermore, it is known that retrieval of fear memory - e.g. by presentation of a CS+ without US - renders this memory labile.<xref rid="R3" ref-type="bibr">3</xref> Subsequent re-consolidation is a protein synthesis-dependent process<xref rid="R3" ref-type="bibr">3</xref>, and it has been suggested that pharmacological disruption of this process may specifically erase human fear memory.<xref rid="R5" ref-type="bibr">5</xref> This would render the combination of specific fear re-activation and pharmacological intervention a potential treatment principle for posttraumatic stress disorder. It is not known whether reconsolidation involves the same signalling cascades as required for initial consolidation; yet there is a suggestion that broad-band MMP inhibition may interfere with fear memory reconsolidation in rodents.<xref rid="R55" ref-type="bibr">55</xref> Hence, impairing human fear re-consolidation with MMP-9 inhibitors is a potential target for further research. This could complement recent efforts<xref rid="R2" ref-type="bibr">2</xref> at finding novel strategies for the treatment of posttraumatic stress disorder, and other anxiety disorders.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><p id="P29"><bold>Supplementary Information</bold> is available at <italic>Molecular Psychiatry's</italic> website.</p><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Information</label><media xlink:href="NIHMS71665-supplement-Supplementary_Information.pdf" mimetype="application" mime-subtype="pdf" orientation="portrait" xlink:type="simple" id="d36e595" position="anchor"/></supplementary-material></sec></body><back><ack id="S19"><title>Acknowledgements</title><p>This work was supported by the Swiss National Science Foundation [320030_1449586/1] and the University of Zurich. The Wellcome Trust Centre for Neuroimaging is supported by core funding from the Wellcome Trust [091593/Z/10/Z]. We thank Samuel Gerster for outstanding technical support and Marc Guitart-Masip for commenting on an initial manuscript draft.</p></ack><fn-group><fn fn-type="COI-statement" id="FN2"><p id="P30"><bold>Conflicts of interest</bold></p><p id="P31">The authors declare no conflict of interest</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LeDoux</surname><given-names>JE</given-names></name></person-group><article-title>Emotion circuits in the brain</article-title><source>Annu Rev Neurosci</source><year>2000</year><volume>23</volume><fpage>155</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">10845062</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kroes</surname><given-names>MCW</given-names></name><name><surname>Schiller</surname><given-names>D</given-names></name><name><surname>LeDoux</surname><given-names>JE</given-names></name><name><surname>Phelps</surname><given-names>EA</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Robbins</surname><given-names>TW</given-names></name><name><surname>Sahakian</surname><given-names>BJ</given-names></name></person-group><article-title>Translational approaches targeting Q7
reconsolidation</article-title><source>Translational Neuropsychopharmacology</source><year>2016</year><publisher-name>Cham: Springer International Publishing</publisher-name><pub-id pub-id-type="doi">10.1007/7854_2015_5008</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nader</surname><given-names>K</given-names></name><name><surname>Schafe</surname><given-names>GE</given-names></name><name><surname>Le Doux</surname><given-names>JE</given-names></name></person-group><article-title>Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval</article-title><source>Nature</source><year>2000</year><volume>406</volume><issue>6797</issue><fpage>722</fpage><lpage>726</lpage><pub-id pub-id-type="pmid">10963596</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiller</surname><given-names>D</given-names></name><name><surname>Monfils</surname><given-names>MH</given-names></name><name><surname>Raio</surname><given-names>CM</given-names></name><name><surname>Johnson</surname><given-names>DC</given-names></name><name><surname>LeDoux</surname><given-names>JE</given-names></name><name><surname>Phelps</surname><given-names>EA</given-names></name></person-group><article-title>Preventing the return of fear in humans using reconsolidation update mechanisms</article-title><source>Nature</source><year>2010</year><volume>463</volume><issue>7277</issue><fpage>49</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">20010606</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kindt</surname><given-names>M</given-names></name><name><surname>Soeter</surname><given-names>M</given-names></name><name><surname>Vervliet</surname><given-names>B</given-names></name></person-group><article-title>Beyond extinction: erasing human fear responses and preventing the return of fear</article-title><source>Nat Neurosci</source><year>2009</year><volume>12</volume><issue>3</issue><fpage>256</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">19219038</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soeter</surname><given-names>M</given-names></name><name><surname>Kindt</surname><given-names>M</given-names></name></person-group><article-title>High trait anxiety: a challenge for disrupting fear memory reconsolidation</article-title><source>PloS one</source><year>2013</year><volume>8</volume><issue>11</issue><fpage>e75239</fpage><pub-id pub-id-type="pmid">24260096</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huntley</surname><given-names>GW</given-names></name></person-group><article-title>Synaptic circuit remodelling by matrix metalloproteinases in health and disease</article-title><source>Nat Rev Neurosci</source><year>2012</year><volume>13</volume><issue>11</issue><fpage>743</fpage><lpage>757</lpage><pub-id pub-id-type="pmid">23047773</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsien</surname><given-names>RY</given-names></name></person-group><article-title>Very long-term memories may be stored in the pattern of holes in the perineuronal net</article-title><source>ProcNatlAcadSciUSA</source><year>2013</year><volume>110</volume><issue>30</issue><fpage>12456</fpage><lpage>12461</lpage></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorg</surname><given-names>BA</given-names></name><name><surname>Berretta</surname><given-names>S</given-names></name><name><surname>Blacktop</surname><given-names>JM</given-names></name><name><surname>Fawcett</surname><given-names>JW</given-names></name><name><surname>Kitagawa</surname><given-names>H</given-names></name><name><surname>Kwok</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Casting a Wide Net: Role of Perineuronal Nets in Neural Plasticity</article-title><source>J Neurosci</source><year>2016</year><volume>36</volume><issue>45</issue><fpage>11459</fpage><lpage>11468</lpage><pub-id pub-id-type="pmid">27911749</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gogolla</surname><given-names>N</given-names></name><name><surname>Caroni</surname><given-names>P</given-names></name><name><surname>Luthi</surname><given-names>A</given-names></name><name><surname>Herry</surname><given-names>C</given-names></name></person-group><article-title>Perineuronal nets protect fear memories from erasure</article-title><source>Science</source><year>2009</year><volume>325</volume><issue>5945</issue><fpage>1258</fpage><lpage>1261</lpage><pub-id pub-id-type="pmid">19729657</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hylin</surname><given-names>MJ</given-names></name><name><surname>Orsi</surname><given-names>SA</given-names></name><name><surname>Moore</surname><given-names>AN</given-names></name><name><surname>Dash</surname><given-names>PK</given-names></name></person-group><article-title>Disruption of the perineuronal net in the hippocampus or medial prefrontal cortex impairs fear conditioning</article-title><source>Learn Mem</source><year>2013</year><volume>20</volume><issue>5</issue><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">23592037</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slaker</surname><given-names>M</given-names></name><name><surname>Churchill</surname><given-names>L</given-names></name><name><surname>Todd</surname><given-names>RP</given-names></name><name><surname>Blacktop</surname><given-names>JM</given-names></name><name><surname>Zuloaga</surname><given-names>DG</given-names></name><name><surname>Raber</surname><given-names>J</given-names></name><etal/></person-group><article-title>Removal of perineuronal nets in the medial prefrontal cortex impairs the acquisition and reconsolidation of a cocaine-induced conditioned place preference memory</article-title><source>J Neurosci</source><year>2015</year><volume>35</volume><issue>10</issue><fpage>4190</fpage><lpage>4202</lpage><pub-id pub-id-type="pmid">25762666</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagy</surname><given-names>V</given-names></name><name><surname>Bozdagi</surname><given-names>O</given-names></name><name><surname>Matynia</surname><given-names>A</given-names></name><name><surname>Balcerzyk</surname><given-names>M</given-names></name><name><surname>Okulski</surname><given-names>P</given-names></name><name><surname>Dzwonek</surname><given-names>J</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory</article-title><source>J Neurosci</source><year>2006</year><volume>26</volume><issue>7</issue><fpage>1923</fpage><lpage>1934</lpage><pub-id pub-id-type="pmid">16481424</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>XB</given-names></name><name><surname>Bozdagi</surname><given-names>O</given-names></name><name><surname>Nikitczuk</surname><given-names>JS</given-names></name><name><surname>Zhai</surname><given-names>ZW</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Huntley</surname><given-names>GW</given-names></name></person-group><article-title>Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine enlargement and long-term potentiation coordinately</article-title><source>ProcNatlAcadSciUSA</source><year>2008</year><volume>105</volume><issue>49</issue><fpage>19520</fpage><lpage>19525</lpage></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorkiewicz</surname><given-names>T</given-names></name><name><surname>Balcerzyk</surname><given-names>M</given-names></name><name><surname>Kaczmarek</surname><given-names>L</given-names></name><name><surname>Knapska</surname><given-names>E</given-names></name></person-group><article-title>Matrix metalloproteinase 9 (MMP-9) is indispensable for long term potentiation in the central and basal but not in the lateral nucleus of the amygdala</article-title><source>Front Cell Neurosci</source><year>2015</year><volume>9</volume><fpage>73</fpage><pub-id pub-id-type="pmid">25814930</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meighan</surname><given-names>PC</given-names></name><name><surname>Meighan</surname><given-names>SE</given-names></name><name><surname>Davis</surname><given-names>CJ</given-names></name><name><surname>Wright</surname><given-names>JW</given-names></name><name><surname>Harding</surname><given-names>JW</given-names></name></person-group><article-title>Effects of matrix metalloproteinase inhibition on short- and long-term plasticity of schaffer collateral/CA1 synapses</article-title><source>J Neurochem</source><year>2007</year><volume>102</volume><issue>6</issue><fpage>2085</fpage><lpage>2096</lpage><pub-id pub-id-type="pmid">17587312</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knapska</surname><given-names>E</given-names></name><name><surname>Lioudyno</surname><given-names>V</given-names></name><name><surname>Kiryk</surname><given-names>A</given-names></name><name><surname>Mikosz</surname><given-names>M</given-names></name><name><surname>Gorkiewicz</surname><given-names>T</given-names></name><name><surname>Michaluk</surname><given-names>P</given-names></name><etal/></person-group><article-title>Reward learning requires activity of matrix metalloproteinase-9 in the central amygdala</article-title><source>J Neurosci</source><year>2013</year><volume>33</volume><issue>36</issue><fpage>14591</fpage><lpage>14600</lpage><pub-id pub-id-type="pmid">24005309</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagy</surname><given-names>V</given-names></name><name><surname>Bozdagi</surname><given-names>O</given-names></name><name><surname>Huntley</surname><given-names>GW</given-names></name></person-group><article-title>The extracellular protease matrix metalloproteinase-9 is activated by inhibitory avoidance learning and required for long-term memory</article-title><source>Learn Mem</source><year>2007</year><volume>14</volume><issue>10</issue><fpage>655</fpage><lpage>664</lpage><pub-id pub-id-type="pmid">17909100</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlsson</surname><given-names>M</given-names></name><name><surname>Hammers</surname><given-names>S</given-names></name><name><surname>Nilsson-Ehle</surname><given-names>I</given-names></name><name><surname>Malmborg</surname><given-names>AS</given-names></name><name><surname>Wretlind</surname><given-names>B</given-names></name></person-group><article-title>Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis</article-title><source>Antimicrobial agents and chemotherapy</source><year>1996</year><volume>40</volume><issue>5</issue><fpage>1104</fpage><lpage>1107</lpage><pub-id pub-id-type="pmid">8723448</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golub</surname><given-names>LM</given-names></name><name><surname>Ramamurthy</surname><given-names>NS</given-names></name><name><surname>McNamara</surname><given-names>TF</given-names></name><name><surname>Greenwald</surname><given-names>RA</given-names></name><name><surname>Rifkin</surname><given-names>BR</given-names></name></person-group><article-title>Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs</article-title><source>Crit Rev Oral Biol Med</source><year>1991</year><volume>2</volume><issue>3</issue><fpage>297</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">1654139</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanemaaijer</surname><given-names>R</given-names></name><name><surname>Visser</surname><given-names>H</given-names></name><name><surname>Koolwijk</surname><given-names>P</given-names></name><name><surname>Sorsa</surname><given-names>T</given-names></name><name><surname>Salo</surname><given-names>T</given-names></name><name><surname>Golub</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells</article-title><source>Advances in dental research</source><year>1998</year><volume>12</volume><issue>2</issue><fpage>114</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">9972133</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Boucsein</surname><given-names>W</given-names></name></person-group><source>Electrodermal activity</source><year>2012</year><publisher-name>Springer</publisher-name><publisher-loc>New York</publisher-loc></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bach</surname><given-names>DR</given-names></name><name><surname>Daunizeau</surname><given-names>J</given-names></name><name><surname>Friston</surname><given-names>KJ</given-names></name><name><surname>Dolan</surname><given-names>RJ</given-names></name></person-group><article-title>Dynamic causal modelling of anticipatory skin conductance responses</article-title><source>Biological psychology</source><year>2010</year><volume>85</volume><issue>1</issue><fpage>163</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">20599582</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staib</surname><given-names>M</given-names></name><name><surname>Castegnetti</surname><given-names>G</given-names></name><name><surname>Bach</surname><given-names>DR</given-names></name></person-group><article-title>Optimising a model-based approach to inferring fear learning from skin conductance responses</article-title><source>J Neurosci Methods</source><year>2015</year><volume>255</volume><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">26291885</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>JS</given-names></name><name><surname>Kalish</surname><given-names>HI</given-names></name><name><surname>Faber</surname><given-names>IE</given-names></name></person-group><article-title>Conditioned fear as revealed by magnitude of startle response to an auditory stimulus</article-title><source>J Exp Psychol</source><year>1951</year><volume>41</volume><issue>5</issue><fpage>317</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">14861383</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grillon</surname><given-names>C</given-names></name><name><surname>Ameli</surname><given-names>R</given-names></name><name><surname>Woods</surname><given-names>SW</given-names></name><name><surname>Merikangas</surname><given-names>K</given-names></name><name><surname>Davis</surname><given-names>M</given-names></name></person-group><article-title>Fear-potentiated startle in humans: effects of anticipatory anxiety on the acoustic blink reflex</article-title><source>Psychophysiology</source><year>1991</year><volume>28</volume><issue>5</issue><fpage>588</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">1758934</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bach</surname><given-names>DR</given-names></name></person-group><article-title>A cost minimisation and Bayesian inference model predicts startle reflex modulation across species</article-title><source>J Theor Biol</source><year>2015</year><volume>370</volume><fpage>53</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">25660056</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khemka</surname><given-names>S</given-names></name><name><surname>Tzovara</surname><given-names>A</given-names></name><name><surname>Gerster</surname><given-names>S</given-names></name><name><surname>Quednow</surname><given-names>BB</given-names></name><name><surname>Bach</surname><given-names>DR</given-names></name></person-group><article-title>Modeling startle eyeblink electromyogram to assess fear learning</article-title><source>Psychophysiology</source><year>2017</year><volume>54</volume><issue>2</issue><fpage>204</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">27753123</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sjouwerman</surname><given-names>R</given-names></name><name><surname>Niehaus</surname><given-names>J</given-names></name><name><surname>Kuhn</surname><given-names>M</given-names></name><name><surname>Lonsdorf</surname><given-names>TB</given-names></name></person-group><article-title>Don't startle me-Interference of startle probe presentations and intermittent ratings with fear acquisition</article-title><source>Psychophysiology</source><year>2016</year><volume>53</volume><issue>12</issue><fpage>1889</fpage><lpage>1899</lpage><pub-id pub-id-type="pmid">27628268</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>M</given-names></name><name><surname>Astrachan</surname><given-names>DI</given-names></name></person-group><article-title>Conditioned fear and startle magnitude: effects of different footshock or backshock intensities used in training</article-title><source>J Exp Psychol Anim Behav Process</source><year>1978</year><volume>4</volume><issue>2</issue><fpage>95</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">670892</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Mano</surname><given-names>H</given-names></name><name><surname>Ganesh</surname><given-names>G</given-names></name><name><surname>Robbins</surname><given-names>T</given-names></name><name><surname>Seymour</surname><given-names>B</given-names></name></person-group><article-title>Dissociable Learning Processes Underlie Human Pain Conditioning</article-title><source>Current biology : CB</source><year>2016</year><volume>26</volume><issue>1</issue><fpage>52</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">26711494</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Schiller</surname><given-names>D</given-names></name><name><surname>Schoenbaum</surname><given-names>G</given-names></name><name><surname>Phelps</surname><given-names>EA</given-names></name><name><surname>Daw</surname><given-names>ND</given-names></name></person-group><article-title>Differential roles of human striatum and amygdala in associative learning</article-title><source>Nat Neurosci</source><year>2011</year><volume>14</volume><issue>10</issue><fpage>1250</fpage><lpage>1252</lpage><pub-id pub-id-type="pmid">21909088</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearce</surname><given-names>JM</given-names></name><name><surname>Hall</surname><given-names>G</given-names></name></person-group><article-title>A Model for Pavlovian Learning - Variations in the Effectiveness of Conditioned But Not of Unconditioned Stimuli</article-title><source>Psychological review</source><year>1980</year><volume>87</volume><issue>6</issue><fpage>532</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">7443916</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faul</surname><given-names>F</given-names></name><name><surname>Erdfelder</surname><given-names>E</given-names></name><name><surname>Lang</surname><given-names>AG</given-names></name><name><surname>Buchner</surname><given-names>A</given-names></name></person-group><article-title>G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences</article-title><source>Behav Res Methods</source><year>2007</year><volume>39</volume><issue>2</issue><fpage>175</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">17695343</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Laux</surname><given-names>L</given-names></name><name><surname>Glanzmann</surname><given-names>P</given-names></name><name><surname>Schaffner</surname><given-names>P</given-names></name><name><surname>Spielberger</surname><given-names>CD</given-names></name></person-group><source>Das State-Trait-Angstinventar</source><year>1981</year><publisher-name>Beltz</publisher-name><publisher-loc>Weinheim</publisher-loc></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hautzinger</surname><given-names>M</given-names></name><name><surname>Bailer</surname><given-names>M</given-names></name><name><surname>Worall</surname><given-names>H</given-names></name><name><surname>Keller</surname><given-names>F</given-names></name></person-group><source>Beck-Depressions-Inventar</source><year>1994</year><publisher-name>Hans Huber</publisher-name><publisher-loc>Bern</publisher-loc></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchner</surname><given-names>WK</given-names></name></person-group><article-title>Age differences in short-term retention of rapidly changing information</article-title><source>J Exp Psychol</source><year>1958</year><volume>55</volume><issue>4</issue><fpage>352</fpage><pub-id pub-id-type="pmid">13539317</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Brickenkamp</surname><given-names>R</given-names></name><name><surname>Schmidt-Atzert</surname><given-names>L</given-names></name><name><surname>Liepmann</surname><given-names>D</given-names></name><name><surname>Schmidt-Atzert</surname><given-names>L</given-names></name></person-group><source>d2-R: Test d2-Revision: Aufmerksamkeits-und Konzentrationstest</source><year>2010</year><publisher-name>Hogrefe</publisher-name></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bach</surname><given-names>DR</given-names></name><name><surname>Friston</surname><given-names>KJ</given-names></name></person-group><article-title>Model-based analysis of skin conductance responses: Towards causal models in psychophysiology</article-title><source>Psychophysiology</source><year>2013</year><volume>50</volume><issue>1</issue><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">23094650</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bach</surname><given-names>DR</given-names></name><name><surname>Flandin</surname><given-names>G</given-names></name><name><surname>Friston</surname><given-names>K</given-names></name><name><surname>Dolan</surname><given-names>RJ</given-names></name></person-group><article-title>Time-series analysis for rapid event-related skin conductance responses</article-title><source>J Neurosci Meth</source><year>2009</year><volume>184</volume><fpage>224</fpage><lpage>234</lpage></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bach</surname><given-names>DR</given-names></name><name><surname>Flandin</surname><given-names>G</given-names></name><name><surname>Friston</surname><given-names>KJ</given-names></name><name><surname>Dolan</surname><given-names>RJ</given-names></name></person-group><article-title>Modelling event-related skin conductance responses</article-title><source>International Journal of Psychophysiology</source><year>2010</year><volume>75</volume><issue>3</issue><fpage>349</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">20093150</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pinheiro</surname><given-names>J</given-names></name><name><surname>Bates</surname><given-names>D</given-names></name></person-group><source>Mixed-effects models in S and S-PLUS</source><year>2006</year><publisher-name>Springer Science &#x00026; Business Media</publisher-name></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatzispyrou</surname><given-names>IA</given-names></name><name><surname>Held</surname><given-names>NM</given-names></name><name><surname>Mouchiroud</surname><given-names>L</given-names></name><name><surname>Auwerx</surname><given-names>J</given-names></name><name><surname>Houtkooper</surname><given-names>RH</given-names></name></person-group><article-title>Tetracycline antibiotics impair mitochondrial function and its experimental use confounds research</article-title><source>Cancer Res</source><year>2015</year><volume>75</volume><issue>21</issue><fpage>4446</fpage><lpage>4449</lpage><pub-id pub-id-type="pmid">26475870</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahler</surname><given-names>E</given-names></name><name><surname>Sullivan</surname><given-names>WJ</given-names></name><name><surname>Cass</surname><given-names>A</given-names></name><name><surname>Braas</surname><given-names>D</given-names></name><name><surname>York</surname><given-names>AG</given-names></name><name><surname>Bensinger</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Doxycycline alters metabolism and proliferation of human cell lines</article-title><source>PloS one</source><year>2013</year><volume>8</volume><issue>5</issue><fpage>e64561</fpage><pub-id pub-id-type="pmid">23741339</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Idzikowski</surname><given-names>C</given-names></name><name><surname>Oswald</surname><given-names>I</given-names></name></person-group><article-title>Interference with human memory by an antibiotic</article-title><source>Psychopharmacology</source><year>1983</year><volume>79</volume><issue>2-3</issue><fpage>108</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">6405417</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>SR</given-names></name></person-group><article-title>REM sleep deprivation and protein synthesis inhibition: Effects on human memory</article-title><source>Sleep</source><year>1974</year><fpage>373</fpage><lpage>376</lpage></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walters</surname><given-names>ET</given-names></name><name><surname>Carew</surname><given-names>TJ</given-names></name><name><surname>Kandel</surname><given-names>ER</given-names></name></person-group><article-title>Associative Learning in Aplysia: evidence for conditioned fear in an invertebrate</article-title><source>Science</source><year>1981</year><volume>211</volume><issue>4481</issue><fpage>504</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">7192881</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falls</surname><given-names>WA</given-names></name><name><surname>Carlson</surname><given-names>S</given-names></name><name><surname>Turner</surname><given-names>JG</given-names></name><name><surname>Willott</surname><given-names>JF</given-names></name></person-group><article-title>Fear-potentiated startle in two strains of inbred mice</article-title><source>Behav Neurosci</source><year>1997</year><volume>111</volume><issue>4</issue><fpage>855</fpage><lpage>861</lpage><pub-id pub-id-type="pmid">9267664</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>CC</given-names></name></person-group><article-title>The effect of amobarbital sodium on conditioned fear as measured by the potentiated startle response in rats</article-title><source>Psychopharmacologia</source><year>1965</year><volume>7</volume><issue>2</issue><fpage>115</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">5830969</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antoniadis</surname><given-names>EA</given-names></name><name><surname>Winslow</surname><given-names>JT</given-names></name><name><surname>Davis</surname><given-names>M</given-names></name><name><surname>Amaral</surname><given-names>DG</given-names></name></person-group><article-title>Role of the primate amygdala in fear-potentiated startle: effects of chronic lesions in the rhesus monkey</article-title><source>J Neurosci</source><year>2007</year><volume>27</volume><issue>28</issue><fpage>7386</fpage><lpage>7396</lpage><pub-id pub-id-type="pmid">17626199</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spence</surname><given-names>KW</given-names></name><name><surname>Runquist</surname><given-names>WN</given-names></name></person-group><article-title>Temporal effects of conditioned fear on the eyelid reflex</article-title><source>J Exp Psychol</source><year>1958</year><volume>55</volume><issue>6</issue><fpage>613</fpage><lpage>616</lpage><pub-id pub-id-type="pmid">13563778</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dziembowska</surname><given-names>M</given-names></name><name><surname>Milek</surname><given-names>J</given-names></name><name><surname>Janusz</surname><given-names>A</given-names></name><name><surname>Rejmak</surname><given-names>E</given-names></name><name><surname>Romanowska</surname><given-names>E</given-names></name><name><surname>Gorkiewicz</surname><given-names>T</given-names></name><etal/></person-group><article-title>Activity-dependent local translation of matrix metalloproteinase-9</article-title><source>J Neurosci</source><year>2012</year><volume>32</volume><issue>42</issue><fpage>14538</fpage><lpage>14547</lpage><pub-id pub-id-type="pmid">23077039</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gawlak</surname><given-names>M</given-names></name><name><surname>Gorkiewicz</surname><given-names>T</given-names></name><name><surname>Gorlewicz</surname><given-names>A</given-names></name><name><surname>Konopacki</surname><given-names>FA</given-names></name><name><surname>Kaczmarek</surname><given-names>L</given-names></name><name><surname>Wilczynski</surname><given-names>GM</given-names></name></person-group><article-title>High resolution in situ zymography reveals matrix metalloproteinase activity at glutamatergic synapses</article-title><source>Neuroscience</source><year>2009</year><volume>158</volume><issue>1</issue><fpage>167</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">18588950</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gale</surname><given-names>GD</given-names></name><name><surname>Anagnostaras</surname><given-names>SG</given-names></name><name><surname>Godsil</surname><given-names>BP</given-names></name><name><surname>Mitchell</surname><given-names>S</given-names></name><name><surname>Nozawa</surname><given-names>T</given-names></name><name><surname>Sage</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Role of the basolateral amygdala in the storage of fear memories across the adult lifetime of rats</article-title><source>J Neurosci</source><year>2004</year><volume>24</volume><issue>15</issue><fpage>3810</fpage><lpage>3815</lpage><pub-id pub-id-type="pmid">15084662</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>TE</given-names></name><name><surname>Wilson</surname><given-names>AR</given-names></name><name><surname>Cocking</surname><given-names>DL</given-names></name><name><surname>Sorg</surname><given-names>BA</given-names></name></person-group><article-title>Inhibition of matrix metalloproteinase activity disrupts reconsolidation but not consolidation of a fear memory</article-title><source>Neurobiology of learning and memory</source><year>2009</year><volume>91</volume><issue>1</issue><fpage>66</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">18824238</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Experimental protocol. (a) Recruitment and exclusion of participants. (b) Study visit time line. (c) Intra-trial procedure. A CS (red or blue screen) was presented for 4 s; 50% of CS+ co-terminated with a 0.5 s US (painful electric stimulation).</p></caption><graphic xlink:href="emss-71665-f001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p><bold>N-back task accuracy</bold>, transformed to Sensitivity index d' = z(Hit Rate) -
z(False Alarm Rate), and Bias = 1/2 * (z(Hit Rate) + z(False Alarm Rate)).
Targets for this transformation are letter repetitions, i.e. a positive bias
implies that participants were more likely to indicate "same
letter" than "different letter". There was no statistically
significant impact of doxycycline on d' or bias (<xref ref-type="supplementary-material" rid="SD1">Supplementary
Information</xref>).</p></caption><graphic xlink:href="emss-71665-f002"/></fig><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Fear retention under extinction, and fear associability during re-learning and initial acquisition.</title><p>(a) Fear retention quotient, based on measured startle eye blink response in a fear retention
session 7 days after acquisition. Condition averages with standard errors from N
= 76 participants and 40 trials per participant; estimated marginal means and
standard errors from LME model; and trial-wise interpolated and averaged data.
(b) Fear associability quotient from fear re-learning immediately after the
retention test, based on measured SCR. Condition averages with standard errors
from N = 71 participants and 8 mini-blocks per participant; estimated marginal
means and standard errors from a trial-by-trial LME model, on 4433 trials from N
= 75 participants; and trial-wise interpolated and averaged data (no data
available for trial 1 which was always reinforced). (c) Fear associability
quotient from acquisition session: N = 65 participants and 16 mini-blocks per
participant; 8646 trials from N = 73 participants. Full statistical results are
found in <xref ref-type="supplementary-material" rid="SD1">Supplementary
Information</xref>. * p &#x0003c; .05; ** p &#x0003c; .01; *** p &#x0003c; .001.</p></caption><graphic xlink:href="emss-71665-f003"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><title>Group characteristics.</title><p>BMI: body-mass index. STAI X1: trait anxiety score. STAI X2: state anxiety score. BDI: depression score. Current: Electric current used for the US. Pain difference: difference in average pain ratings of 14 stimuli before and after the acquisition test. Accuracy: % correct responses in incidental task. Performance: % responses in incidental task. d2-measures: performance of attention; speed; % errors. p: p-value of a 2-sample t-test between the two groups. Questionnaires (STAI, BDI) were filled in before drug ingestion. STAI, BDI, and pain difference, were entered into the statistical model for the outcome measures as covariates.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="2" rowspan="1">Placebo group</th><th align="left" colspan="2" rowspan="1">Doxycycline group</th><th align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Sex</bold></td><td align="left" rowspan="1" colspan="1">20 male</td><td align="left" rowspan="1" colspan="1">18 female</td><td align="left" rowspan="1" colspan="1">20 male</td><td align="left" rowspan="1" colspan="1">18 female</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="6" align="left" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">p</td></tr><tr><td colspan="6" align="left" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Age</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;23.05</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;2.65</td><td align="left" rowspan="1" colspan="1">&#x000a0;23.76</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;4.25</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;0.385</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>BMI</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;22.05</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;2.45</td><td align="left" rowspan="1" colspan="1">&#x000a0;22.65</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;2.47</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;0.300</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>STAI X1</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;32.38</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;6.70</td><td align="left" rowspan="1" colspan="1">&#x000a0;33.74</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;7.07</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;0.395</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>STAI X2</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;38.03</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;6.48</td><td align="left" rowspan="1" colspan="1">&#x000a0;38.48</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;6.28</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;0.765</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>BDI</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;3.37</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;2.98</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;4.50</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;4.27</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;0.185</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Current</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;3.55</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;1.21</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;3.72</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;1.27</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;0.552</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Pain difference</bold></td><td align="left" rowspan="1" colspan="1">-15.63</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;15.23</td><td align="left" rowspan="1" colspan="1">&#x000a0;-8.35</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;17.70</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;0.101</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Accuracy</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;0.85</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;0.08</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;0.82</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;0.10</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;0.200</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Performance</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;0.97</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;0.08</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;0.95</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;0.17</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;0.511</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>d2 performance of attention</bold></td><td align="left" rowspan="1" colspan="1">178.71</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;30.65</td><td align="left" rowspan="1" colspan="1">176.68</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;35.67</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;0.791</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>d2 speed</bold></td><td align="left" rowspan="1" colspan="1">204.21</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;33.53</td><td align="left" rowspan="1" colspan="1">202.84</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;35.83</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;0.864</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>d2 errors</bold></td><td align="left" rowspan="1" colspan="1">&#x000a0;12.01</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;10.31</td><td align="left" rowspan="1" colspan="1">&#x000a0;12.30</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;12.88</td><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;0.916</td></tr></tbody></table></table-wrap></floats-group></article>